uniQure N.V. Research and Development Expense
uniQure N.V. (QURE) reported Research and Development Expense of $29.18 million for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-05-05
- uniQure N.V. research and development expense for the quarter ending 2026-03-31 was $29.18M, a 19.27% decline year-over-year.
- uniQure N.V. research and development expense for the quarter ending 2025-12-31 was $34.78M, a 10.44% decline year-over-year.
- uniQure N.V. research and development expense for the quarter ending 2025-09-30 was $34.37M, a 12.33% increase year-over-year.
- uniQure N.V. research and development expense for the quarter ending 2025-06-30 was $35.38M, a 5.13% increase year-over-year.
- uniQure N.V. research and development expense for fiscal 2025 was $140.67M, a 2.16% decline from fiscal 2024.
- uniQure N.V. research and development expense for fiscal 2024 was $143.78M, a 33.08% decline from fiscal 2023.
- uniQure N.V. research and development expense for fiscal 2023 was $214.86M, a 8.74% increase from fiscal 2022.
- uniQure N.V. research and development expense for fiscal 2022 was $197.59M, a 37.65% increase from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-03-31 | $29.18M 10-Q · filed 2026-05-05 | $63.96M derived: sum of 2 quarters · filed 2026-05-05 | $98.33M derived: sum of 3 quarters · filed 2026-05-05 | $133.71M derived: sum of 4 quarters · filed 2026-05-05 |
| 2025-12-31 | $34.78M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $69.15M derived: sum of 2 quarters · filed 2026-03-02 | $104.53M derived: sum of 3 quarters · filed 2026-03-02 | $140.67M 10-K · filed 2026-03-02 |
| 2025-09-30 | $34.37M 10-Q · filed 2025-11-10 | $69.75M derived: sum of 2 quarters · filed 2025-11-10 | $105.89M 10-Q · filed 2025-11-10 | $144.73M derived: sum of 4 quarters · filed 2026-05-05 |
| 2025-06-30 | $35.38M 10-Q · filed 2025-07-29 | $71.52M 10-Q · filed 2025-07-29 | $110.36M derived: sum of 3 quarters · filed 2026-05-05 | $140.96M derived: sum of 4 quarters · filed 2026-05-05 |
| 2025-03-31 | $36.14M 10-Q · filed 2026-05-05 | $74.98M derived: sum of 2 quarters · filed 2026-05-05 | $105.58M derived: sum of 3 quarters · filed 2026-05-05 | $139.23M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | $38.84M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $69.44M derived: sum of 2 quarters · filed 2026-03-02 | $103.09M derived: sum of 3 quarters · filed 2026-03-02 | $143.78M 10-K · filed 2026-03-02 |
| 2024-09-30 | $30.59M 10-Q · filed 2025-11-10 | $64.25M derived: sum of 2 quarters · filed 2025-11-10 | $104.94M 10-Q · filed 2025-11-10 | $147.56M derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-06-30 | $33.66M 10-Q · filed 2025-07-29 | $74.35M 10-Q · filed 2025-07-29 | $116.97M derived: sum of 3 quarters · filed 2026-03-02 | $182.37M derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-03-31 | $40.69M 10-Q · filed 2025-05-09 | $83.31M derived: sum of 2 quarters · filed 2026-03-02 | $148.71M derived: sum of 3 quarters · filed 2026-03-02 | $194.75M derived: sum of 4 quarters · filed 2026-03-02 |
| 2023-12-31 | $42.62M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $108.02M derived: sum of 2 quarters · filed 2026-03-02 | $154.06M derived: sum of 3 quarters · filed 2026-03-02 | $214.86M 10-K · filed 2026-03-02 |
| 2023-09-30 | $65.40M 10-Q · filed 2024-11-05 | $111.44M derived: sum of 2 quarters · filed 2024-11-05 | $172.25M 10-Q · filed 2024-11-05 | $230.57M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $46.04M 10-Q · filed 2024-08-01 | $106.84M 10-Q · filed 2024-08-01 | $165.17M derived: sum of 3 quarters · filed 2025-02-27 | $213.24M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $60.81M 10-Q · filed 2024-05-07 | $119.14M derived: sum of 2 quarters · filed 2025-02-27 | $167.21M derived: sum of 3 quarters · filed 2025-02-27 | $213.40M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $58.33M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $106.40M derived: sum of 2 quarters · filed 2025-02-27 | $152.59M derived: sum of 3 quarters · filed 2025-02-27 | $197.59M 10-K · filed 2025-02-27 |
| 2022-09-30 | $48.07M 10-Q · filed 2023-11-07 | $94.26M derived: sum of 2 quarters · filed 2023-11-07 | $139.26M 10-Q · filed 2023-11-07 | $181.60M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-06-30 | $46.19M 10-Q · filed 2023-08-01 | $91.19M 10-Q · filed 2023-08-01 | $133.53M derived: sum of 3 quarters · filed 2024-02-28 | $169.97M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-03-31 | $45.00M 10-Q · filed 2023-05-09 | $87.34M derived: sum of 2 quarters · filed 2024-02-28 | $123.77M derived: sum of 3 quarters · filed 2024-02-28 | $156.52M derived: sum of 4 quarters · filed 2024-02-28 |
| 2021-12-31 | $42.34M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $78.77M derived: sum of 2 quarters · filed 2024-02-28 | $111.52M derived: sum of 3 quarters · filed 2024-02-28 | $143.55M 10-K · filed 2024-02-28 |
| 2021-09-30 | $36.43M 10-Q · filed 2022-11-02 | $69.18M derived: sum of 2 quarters · filed 2022-11-02 | $101.21M 10-Q · filed 2022-11-02 | $133.52M derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-06-30 | $32.75M 10-Q · filed 2022-08-08 | $64.78M 10-Q · filed 2022-08-08 | $97.09M derived: sum of 3 quarters · filed 2023-02-27 | $133.39M derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-03-31 | $32.66M 10-Q · filed 2022-05-02 | $64.34M derived: sum of 2 quarters · filed 2023-02-27 | $100.64M derived: sum of 3 quarters · filed 2023-02-27 | $129.04M derived: sum of 4 quarters · filed 2023-02-27 |
| 2020-12-31 | $31.68M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | $67.99M derived: sum of 2 quarters · filed 2023-02-27 | $96.39M derived: sum of 3 quarters · filed 2023-02-27 | $122.40M 10-K · filed 2023-02-27 |
| 2020-09-30 | $36.30M 10-Q · filed 2021-10-25 | $64.70M derived: sum of 2 quarters · filed 2021-10-25 | $90.72M 10-Q · filed 2021-10-25 | $117.21M derived: sum of 4 quarters · filed 2022-02-25 |
| 2020-06-30 | $28.40M 10-Q · filed 2021-07-26 | $54.41M 10-Q · filed 2021-07-26 | $80.91M derived: sum of 3 quarters · filed 2022-02-25 | $104.46M derived: sum of 4 quarters · filed 2022-02-25 |
| 2020-03-31 | $26.01M 10-Q · filed 2021-05-10 | $52.51M derived: sum of 2 quarters · filed 2022-02-25 | $76.06M derived: sum of 3 quarters · filed 2022-02-25 | $100.21M derived: sum of 4 quarters · filed 2022-02-25 |
| 2019-12-31 | $26.49M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-25 | $50.05M derived: sum of 2 quarters · filed 2022-02-25 | $74.20M derived: sum of 3 quarters · filed 2022-02-25 | $94.74M 10-K · filed 2022-02-25 |
| 2019-09-30 | $23.55M 10-Q · filed 2020-10-27 | $47.71M derived: sum of 2 quarters · filed 2020-10-27 | $68.25M 10-Q · filed 2020-10-27 | $86.96M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-06-30 | $24.15M 10-Q · filed 2020-07-30 | $44.69M 10-Q · filed 2020-07-30 | $63.41M derived: sum of 3 quarters · filed 2021-03-01 | $83.95M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-03-31 | $20.54M 10-Q · filed 2020-04-29 | $39.25M derived: sum of 2 quarters · filed 2021-03-01 | $59.80M derived: sum of 3 quarters · filed 2021-03-01 | $78.29M derived: sum of 4 quarters · filed 2021-03-01 |
| 2018-12-31 | $18.72M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $39.26M derived: sum of 2 quarters · filed 2021-03-01 | $57.75M derived: sum of 3 quarters · filed 2021-03-01 | $74.81M 10-K · filed 2021-03-01 |
| 2018-09-30 | $20.54M 10-Q · filed 2019-10-28 | $39.03M derived: sum of 2 quarters · filed 2019-10-28 | $56.09M 10-Q · filed 2019-10-28 | $74.30M derived: sum of 4 quarters · filed 2020-03-02 |
| 2018-06-30 | $18.49M 10-Q · filed 2019-07-29 | $35.55M 10-Q · filed 2019-07-29 | $53.76M derived: sum of 3 quarters · filed 2020-03-02 | $73.86M derived: sum of 4 quarters · filed 2020-03-02 |
| 2018-03-31 | $17.06M 10-Q · filed 2019-04-29 | $35.27M derived: sum of 2 quarters · filed 2020-03-02 | $55.37M derived: sum of 3 quarters · filed 2020-03-02 | $72.24M derived: sum of 4 quarters · filed 2020-03-02 |
| 2017-12-31 | $18.21M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-02 | $38.31M derived: sum of 2 quarters · filed 2020-03-02 | $55.18M derived: sum of 3 quarters · filed 2020-03-02 | $72.17M 10-K · filed 2020-03-02 |
| 2017-09-30 | $20.10M 10-Q · filed 2018-11-06 | $36.97M derived: sum of 2 quarters · filed 2018-11-06 | $53.96M 10-Q · filed 2018-11-06 | $73.94M derived: sum of 4 quarters · filed 2019-02-28 |
| 2017-06-30 | $16.87M 10-Q · filed 2018-08-08 | $33.86M 10-Q · filed 2018-08-08 | $53.84M derived: sum of 3 quarters · filed 2019-02-28 | $70.44M derived: sum of 4 quarters · filed 2019-02-28 |
| 2017-03-31 | $16.99M 10-Q · filed 2018-04-30 | $36.97M derived: sum of 2 quarters · filed 2019-02-28 | $53.58M derived: sum of 3 quarters · filed 2019-02-28 | $72.80M derived: sum of 4 quarters · filed 2019-02-28 |
| 2016-12-31 | $19.98M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-28 | $36.58M derived: sum of 2 quarters · filed 2019-02-28 | $55.80M derived: sum of 3 quarters · filed 2019-02-28 | $72.51M 10-K · filed 2019-02-28 |
| 2016-09-30 | $16.60M 10-Q · filed 2017-11-01 | $35.83M derived: sum of 2 quarters · filed 2017-11-01 | $52.53M 10-Q · filed 2017-11-01 | |
| 2016-06-30 | $19.22M 10-Q · filed 2017-08-08 | $35.93M 10-Q · filed 2017-08-08 | ||
| 2016-03-31 | $16.71M 10-Q · filed 2017-05-09 | |||
| 2015-12-31 | $59.13M 10-K · filed 2018-03-14 | |||
| 2014-12-31 | $43.77M 10-K · filed 2017-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |